Access Bio Inc

950130.KS

950130.KSAccess Bio Inc KR flag

Korea Exchange

6,390.00

KRW

-10.00

(-0.16%)

Mar 31Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Return %

Stock

S&P500

-1.84

12.07

-64.50

62.30

271.51

98.08

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	2,239.38	1,924.13	- -	1,265.62	1,281.67	1,131.2	1,565.69	1,513.02	3,603.02	14,200.87	29,974.76	9,999.42	- -	2,729.42
Basic EPS, GAAP	451	329	- -	45	12	-249	-165	-618	1,428	5,333	10,051	-91	- -	-268.95
Free Cash Flow per Basic Share	-31	-82.91	- -	-135.64	-388.09	-430.09	-362.26	-136.1	738.48	3,637.1	10,155.93	-3,515	- -	-613.27
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	841.54	- -	- -
Book Value per Share	595.83	736.56	- -	725.72	842.54	491.04	310.57	-310.17	1,075.64	6,638.31	17,177.37	16,357.5	- -	17,809.33
Tangible Book Value per Share	1,146.15	1,904.63	- -	2,444.29	2,366.68	1,704.81	1,290.1	802.62	2,506.79	8,106.15	18,109.79	16,805.26	- -	17,896.92
Basic Weighted Avg Shares	17	24	- -	28	25	26	26	28	34	36	34	35	- -	36
Sales/Revenue/Turnover	36,998	45,840	32,305	35,583	32,486	29,465	40,239	43,059	121,797	505,112	1,033,863	348,643	112,463	98,353
Operating Margin (%)	23	24.86	7.28	0.02	-2.15	-23.27	-13.37	-18.67	56.41	51.5	45.42	6.29	-3.72	-14.93
Depreciation Expense	547	696	1,060	1,777	2,253	2,533	3,072	3,420	3,414	6,064	10,826	15,960	20,078	20,471
Net Income, GAAP	7,451	7,838	2,432	1,265	304	-6,486	-4,241	-17,588	48,272	189,690	346,670	-3,173	-348	-9,691
Effective Tax Rate (%)	31.48	35.43	28.33	71.45	- -	- -	- -	- -	23.47	25.97	24.57	- -	- -	16.04
Profit Margin (%)	20.14	17.1	7.53	3.56	0.94	-22.01	-10.54	-40.85	39.63	37.55	33.53	-0.91	-0.31	-9.85
Working Capital	11,492	35,146	45,008	43,680	55,775	18,057	17,307	8,169	42,308	189,940	519,440	374,416	459,840	452,320
LT Debt	251	212	183	156	28,926	18,475	24,167	22,864	12,431	12,008	62,442	59,714	45,906	41,827
Total Equity	21,707	50,197	68,584	76,882	69,661	54,090	43,415	27,900	86,681	290,047	626,098	587,141	652,405	645,488
Return on Invested Capital (%)	50.31	19.7	2.75	- -	- -	- -	- -	- -	51.07	88.38	76.97	- -	- -	- -
Return on Capital (%)	158.94	56.28	12.33	6.37	- -	- -	- -	- -	84.15	96.8	70.68	- -	- -	0.64
Return on Common Equity (%)	151.38	57.23	12.66	6.13	1.46	-37.99	-40.83	- -	- -	139.23	83.68	-0.55	-0.06	-1.56

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	50.4%	93.65%	-67.74%
Net Income, GAAP	-226.49%	-37.74%	-89.05%
Free Cash Flow	-37.03%	-81.01%	-114.57%
Total Cash Common Dividend	- -	- -	- -
Total Equity	49.09%	113.21%	11.12%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

Sector: Healthcare
Industry: Medical - Diagnostics & Research
Address
IPO Date: May 30, 2013
Similar Companies: Prenetics Global Limited (PRE)
DarioHealth Corp. (DRIO)
Epigenomics AG (EPGNY)
Abingdon Health Plc (ABDXF)
Enzo Biochem, Inc. (ENZB)
Precision System Science Co., Ltd. (PCNEF)
Business: Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	2,239.38	1,924.13	- -	1,265.62	1,281.67	1,131.2	1,565.69	1,513.02	3,603.02	14,200.87	29,974.76	9,999.42	- -	2,729.42
Basic EPS, GAAP	451	329	- -	45	12	-249	-165	-618	1,428	5,333	10,051	-91	- -	-268.95
Free Cash Flow per Basic Share	-31	-82.91	- -	-135.64	-388.09	-430.09	-362.26	-136.1	738.48	3,637.1	10,155.93	-3,515	- -	-613.27
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	841.54	- -	- -
Book Value per Share	595.83	736.56	- -	725.72	842.54	491.04	310.57	-310.17	1,075.64	6,638.31	17,177.37	16,357.5	- -	17,809.33
Tangible Book Value per Share	1,146.15	1,904.63	- -	2,444.29	2,366.68	1,704.81	1,290.1	802.62	2,506.79	8,106.15	18,109.79	16,805.26	- -	17,896.92
Basic Weighted Avg Shares	17	24	- -	28	25	26	26	28	34	36	34	35	- -	36
Sales/Revenue/Turnover	36,998	45,840	32,305	35,583	32,486	29,465	40,239	43,059	121,797	505,112	1,033,863	348,643	112,463	98,353
Operating Margin (%)	23	24.86	7.28	0.02	-2.15	-23.27	-13.37	-18.67	56.41	51.5	45.42	6.29	-3.72	-14.93
Depreciation Expense	547	696	1,060	1,777	2,253	2,533	3,072	3,420	3,414	6,064	10,826	15,960	20,078	20,471
Net Income, GAAP	7,451	7,838	2,432	1,265	304	-6,486	-4,241	-17,588	48,272	189,690	346,670	-3,173	-348	-9,691
Effective Tax Rate (%)	31.48	35.43	28.33	71.45	- -	- -	- -	- -	23.47	25.97	24.57	- -	- -	16.04
Profit Margin (%)	20.14	17.1	7.53	3.56	0.94	-22.01	-10.54	-40.85	39.63	37.55	33.53	-0.91	-0.31	-9.85
Working Capital	11,492	35,146	45,008	43,680	55,775	18,057	17,307	8,169	42,308	189,940	519,440	374,416	459,840	452,320
LT Debt	251	212	183	156	28,926	18,475	24,167	22,864	12,431	12,008	62,442	59,714	45,906	41,827
Total Equity	21,707	50,197	68,584	76,882	69,661	54,090	43,415	27,900	86,681	290,047	626,098	587,141	652,405	645,488
Return on Invested Capital (%)	50.31	19.7	2.75	- -	- -	- -	- -	- -	51.07	88.38	76.97	- -	- -	- -
Return on Capital (%)	158.94	56.28	12.33	6.37	- -	- -	- -	- -	84.15	96.8	70.68	- -	- -	0.64
Return on Common Equity (%)	151.38	57.23	12.66	6.13	1.46	-37.99	-40.83	- -	- -	139.23	83.68	-0.55	-0.06	-1.56

	Sep'24	Dec'24	Mar'25
ST Debt	4,883	20,094	22,082
LT Borrowings	14,600	- -	- -
LT Finance Leases	42,494	45,906	41,827
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	35	35	- -
Market Capitalization	237	- -	- -

	Sep'24	Dec'24	Mar'25
Total Current Assets	412,200	500,243	481,591
Accounts Receivable, Net	6,662	7,633	6,311
Cash, Cash Equivalents & STI	361,169	454,847	440,912
Inventories	24,323	23,460	18,852
Total Current Liabilities	23,475	40,403	29,271
Payables & Accruals	- -	- -	- -
ST Debt	4,883	20,094	22,082
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	239,388	65,040	3,051	36,253	348,643
2024	35,109	25,088	21,698	29,861	112,463
2025	21,707	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	1,212	-738	-208	- -	-91
2024	80	40	-135	- -	- -
2025	-189	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	- -	- -	21.19	- -	841.54
2024	- -	- -	- -	- -	- -
2025	- -	- -	- -	- -	- -

Access Bio Inc

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year